NRXP vs AXSM vs ALTO vs INMB vs ATAI

For growth investors, INmune Bio, Inc.

(INMB) is the stronger pick with 257. 1% revenue growth year-over-year, versus -4. 9% for Alto Ingredients, Inc. (ALTO). Alto Ingredients, Inc. (ALTO) offers the better valuation at 28. 4x trailing P/E (15. 4x forward), making it the more compelling value choice. Analysts rate Axsome Therapeutics, Inc. (AXSM) a "Buy" — based on 25 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Axsome Therapeutics, Inc.

(AXSM) delivered a total return of +286. 4%, compared to -99. 1% for NRx Pharmaceuticals, Inc. (NRXP). Over 10 years, the gap is even starker: AXSM returned +1886% versus NRXP's -96. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Alto Ingredients, Inc.

(ALTO) is the lower-risk stock at 0. 30β versus INmune Bio, Inc. 's 2. 45β — meaning INMB is approximately 708% more volatile than ALTO relative to the S&P 500. On balance sheet safety, INmune Bio, Inc. (INMB) carries a lower debt/equity ratio of 4% versus 3% for Axsome Therapeutics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), INmune Bio, Inc.

(INMB) is pulling ahead at 257. 1% versus -4. 9% for Alto Ingredients, Inc. (ALTO). On earnings-per-share growth, the picture is similar: Alto Ingredients, Inc. grew EPS 119. 5% year-over-year, compared to -272. 0% for Atai Beckley N. V. Over a 3-year CAGR, AXSM leads at 133. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Alto Ingredients, Inc.

(ALTO) is the more profitable company, earning 1. 5% net margin versus -918. 7% for INmune Bio, Inc. — meaning it keeps 1. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALTO leads at 0. 8% versus -617. 4% for INMB. At the gross margin level — before operating expenses — INMB leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for ATAI: 199.

3% to $12. 00.

In this comparison, ALTO (0.

4% yield) pays a dividend. NRXP, AXSM, INMB, ATAI do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Axsome Therapeutics, Inc.

(AXSM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 69), +1886% 10Y return). INmune Bio, Inc. (INMB) carries a higher beta of 2. 45 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (AXSM: +1886%, INMB: -82. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (NRXP (Healthcare) and AXSM (Healthcare) and ALTO (Basic Materials) and INMB (Healthcare) and ATAI (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: NRXP is a small-cap quality compounder stock; AXSM is a mid-cap high-growth stock; ALTO is a small-cap quality compounder stock; INMB is a small-cap high-growth stock; ATAI is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.